Lindsey K. Symons
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lindsey K. Symons has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Bruce A. Lessey
Department of Obstetrics and Gynecology Atrium Health Wake Forest Baptist Winston‐Salem North Carolina USA
1 shared publication - Chandrakant Tayade
Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, Canada
1 shared publication - Harshavardhan Lingegowda
Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, Canada
1 shared publication - Jessica E. Miller
Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, Canada
1 shared publication - Madhuri Koti
Queen's University
1 shared publication - Olga Bougie
University of Toronto, Toronto, Ontario, Canada, Department of Obstetrics and Gynaecology, Sinai Health System, Toronto, Ontario, Canada
1 shared publication
Latest Publications
- Open Access
- 8 December 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (23)
IL-33 activates group 2 innate lymphoid cell expansion and modulates endometriosis
Chronic inflammation and localized alterations in immune cell function are suspected to contribute to the progression of endometriosis and its associated symptoms. In particular, the alarmin IL-33 is elevated in the plasma, peritoneal fluid, and endometriotic lesions from patients with endometriosis; however, the exact role of IL-33 in the pathophysiology of endometriosis is not well understood. In this study, we demonstrate, in both humans and a murine model, that IL-33 contributes to the expansion of group 2 innate lymphoid cells (ILC2s), and this IL-33–induced ILC2 expansion modulates the endometriosis lesion microenvironment. Importantly, we show that IL-33 drives hallmarks of severe endometriosis, including elevated inflammation, lesion proliferation, and fibrosis, and that this IL-33–induced aggravation is mediated by ILC2s. Finally, we demonstrate the functionality of IL-33 neutralization as a promising and potentially novel therapeutic avenue for treating the debilitating symptoms of endometriosis.
- 8 December 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (23)
Open AccessIL-33 activates group 2 innate lymphoid cell expansion and modulates endometriosis
Chronic inflammation and localized alterations in immune cell function are suspected to contribute to the progression of endometriosis and its associated symptoms. In particular, the alarmin IL-33 is elevated in the plasma, peritoneal fluid, and endometriotic lesions from patients with endometriosis; however, the exact role of IL-33 in the pathophysiology of endometriosis is not well understood. In this study, we demonstrate, in both humans and a murine model, that IL-33 contributes to the expansion of group 2 innate lymphoid cells (ILC2s), and this IL-33–induced ILC2 expansion modulates the endometriosis lesion microenvironment. Importantly, we show that IL-33 drives hallmarks of severe endometriosis, including elevated inflammation, lesion proliferation, and fibrosis, and that this IL-33–induced aggravation is mediated by ILC2s. Finally, we demonstrate the functionality of IL-33 neutralization as a promising and potentially novel therapeutic avenue for treating the debilitating symptoms of endometriosis.